Investing.com — ARS Pharmaceuticals stock experienced a significant uptick, surging 11%, marking its biggest intraday leap since August.

This surge was prompted by the company’s announcement of preliminary fourth-quarter net income for its allergy spray, Neffy, which exceeded analyst forecasts.

Preliminary net product revenue for Neffy in the fourth quarter was approximately $6.5 million. This figure significantly exceeded the average estimate of $3.11 million projected by analysts, as polled by Bloomberg.

By 2024, total net product sales will reach $7.1 million. This income was generated after the allergy spray became accessible to wholesalers and pharmacies on September 23.

Looking ahead to 2025, ARS Pharmaceuticals has indicated its intention to increase demand and gain more traction among its target prescribers.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.